menu
    • menu
    [{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Termination","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Galderma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Ipsen"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"QM1114-DP","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"QM1114-DP","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"QM1114-DP","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"RelabotulinumtoxinA","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Acquisition","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Agreement","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Agreement","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota Spores, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Aimmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Peanut (Arachis Hypogaea) Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0.46999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.46999999999999997,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Biotin","moa":"||Krebs cycle activatior","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Aimmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Acquisition","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":1.9299999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":1.9299999999999999,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Allergy Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Collaboration","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Allergy Partners","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Allergy Partners"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Stallergenes Greer","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2023","type":"Divestment","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Nestle Health Sciences SA \/ Stallergenes Greer","highestDevelopmentStatusID":"15","companyTruncated":"Nestle Health Sciences SA \/ Stallergenes Greer"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nestle Health Sciences SA","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Valbiotis","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Valbiotis","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Partnership","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Nestle Health Sciences SA","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Toripalimab","moa":"Programmed cell death protein 1","graph1":"Endocrinology","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Endocrinology","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Codexis","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Codexis"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CDX-6114","moa":"Phenylalanine","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Enterome","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"EB1010","moa":"Monoamine transporter","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"4","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Senda Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"4","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Medidata Solutions | SAS Institute | Veeva Systems | Cognizant Technology Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Intact Cow\\'S Milk Protein Formula","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Medidata Solutions | SAS Institute | Veeva Systems | Cognizant Technology Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Medidata Solutions | SAS Institute | Veeva Systems | Cognizant Technology Solutions"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Ole Enzymatically Treated","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Olive Leaf Extract","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Mulberry Leaves Extract","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Cream","sponsorNew":"Galderma \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"GALDERMA LABS LP","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"GALDERMA LABS LP","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"GALDERMA LABS LP \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GALDERMA LABS LP \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Certara","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Alastin Skincare","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Acquisition","leadProduct":"Herbal Extract","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Alastin Skincare","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"Herbal Extract","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Arachis Hypogaea Allergen","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Aimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aimmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aimmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trifarotene","moa":"Retinoic acid receptor gamma","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Cetaphil","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Cetaphil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Cetaphil","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Acded","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"8","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Galderma","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"XmAb7195","moa":"IgE receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Aimmune Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Aimmune Therapeutics \/ Aimmune Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Aimmune Therapeutics \/ Aimmune Therapeutics"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Collaboration","leadProduct":"CDX-7108","moa":"Pancreatic enzyme","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"2","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bifidobacterium Longum","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Nestle Health Sciences SA \/ Syneos Health | Medidata Solutions | McMaster University | CaligorRx, Inc."},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Betaquik MCT Supplement","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Fiber","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Malt Ingredient","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Medrio, Inc | SAS Institute | Veeva Systems","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Starter Infant Formula","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Medrio, Inc | SAS Institute | Veeva Systems","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Medrio, Inc | SAS Institute | Veeva Systems"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Betaquik","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Healint Pte Ltd | Diex Research Sherbrooke Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Nutritional Ketogenic Supplement","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Healint Pte Ltd | Diex Research Sherbrooke Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Healint Pte Ltd | Diex Research Sherbrooke Inc."},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"MAG Oil","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Roquette Glucidex 2","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Sondalis Hp","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pediatrics","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"HMO","moa":"Undisclosed","graph1":"Pediatrics","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Peking Union Medical College Hospital"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nutren Diabetes","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"MAG Oil","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Low Carbohydrate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Alfamino Junior","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"UCAM university","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Pre-Activity Shot","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ UCAM university","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ UCAM university"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"EHF","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Milk","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Sun Yat-sen University","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Sun Yat-sen University"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"Vaginal pH","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galderma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Galderma \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Bioiberica","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Bioiberica","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Bioiberica"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Whey Protein","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Whey Protein","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Whey Protein","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Exogenous Ketone Salt","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Phgg","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Thickenup Gel Express","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NAM\/B6","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Reducose","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Pruvin R","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Ketogenic Formulae","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Plant-Based Meal","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Low Carb Meals","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Exogenous Ketone Salt","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Phgg","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Oligomalt","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Compleat 1.5 HP","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Compleat","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Peptamen","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Brainxpert","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Imperial College London | Imperial Clinical Trials Unit","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Spice Blend","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Imperial College London | Imperial Clinical Trials Unit","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Imperial College London | Imperial Clinical Trials Unit"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Galderma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Nemolizumab","moa":"Interleukin-31 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Galderma \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Low Sodium Beverage","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Nestle Health Sciences SA

    Menu

    Nestle Health Sciences SA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nestle Health Sciences SA

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nutritional Solution with Intragastric Gelation for Tolerance & Appetite

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Overweight.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 17, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Galderma

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed

                            Galderma

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nemolizumab PK/PD Safety and Efficacy In Adults with Chronic Pruritus

                            Details : Nemolizumab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Pruritus.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 20, 2025

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Galderma

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed

                            Galderma

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Nemolizumab for the Treatment of Adults with Systemic Sclerosis

                            Details : Nemolizumab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Scleroderma, Systemic.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 02, 2025

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nestle Health Sciences SA

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Undisclosed

                            Recipient : D'Or Institute for Research and Education

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tolerance to Immunomodulatory Nutritional Therapy in Oncology Patients

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Malnutrition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 15, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Undisclosed

                            Recipient : D'Or Institute for Research and Education

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nestle Health Sciences SA

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Low Sodium Beverage

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hydration to be Optimized (H2O) with a Low-sodium Beverage

                            Details : Low Sodium Beverage is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            May 20, 2025

                            Lead Product(s) : Low Sodium Beverage

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nestle Health Sciences SA

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Milk

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Sun Yat-sen University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Visualization of Functional Milk Efficacy on Perceived Benefits

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            March 07, 2025

                            Lead Product(s) : Milk

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Sun Yat-sen University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nestle Health Sciences SA

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EHF

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CMPA-GO Study: Growth and Safety Outcomes in Infants With CMPA Fed a Novel Extensively Hydrolyzed Formula

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            February 17, 2025

                            Lead Product(s) : EHF

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Galderma

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed

                            Galderma

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Galderma’s Nemluvio® Approved in EU for Atopic Dermatitis & Prurigo

                            Details : Nemluvio (nemolizumab) is a humanized anti-human IL-31 receptor A monoclonal antibody, approved for the treatment of patients with moderate-to-severe atopic dermatitis.

                            Product Name : Nemluvio

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 14, 2025

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Galderma

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed

                            Galderma

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RelabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Galderma’s Relfydess Shows Fast, Long-Lasting Aesthetic Results

                            Details : Relfydess (relabotulinumtoxinA) is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology for moderate to severe vertical frown lines.

                            Product Name : Relfydess

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 30, 2025

                            Lead Product(s) : RelabotulinumtoxinA

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Galderma

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed

                            Galderma

                            Switzerland arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CHMP Recommends Nemolizumab Approval for Atopic Dermatitis and Prurigo Nodularis

                            Details : Nemluvio (nemolizumab) is a humanized anti-human IL-31 receptor A monoclonal antibody, approved for the treatment of patients with moderate-to-severe atopic dermatitis & prurigo nodularis.

                            Product Name : Nemluvio

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 13, 2024

                            Lead Product(s) : Nemolizumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth